Enthera Overview

  • Year Founded
  • 2016

Year Founded

  • Status
  • Private

  • Employees
  • 16

Employees

  • Latest Deal Type
  • Series A

  • Latest Deal Amount
  • $42.6M

  • Investors
  • 10

Enthera General Information

Description

Developer of biotherapeutics intended to treat auto-immune disorders. The company's pipelined products target pathways involved in cell apoptosis in the gut, pancreas, and other organs which plays a key role in the development of type 1 diabetes and inflammatory bowel disease, enabling the medical community to effectively combat intractable autoimmune diseases.

Contact Information

Website
www.entherapharmaceuticals.com
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Corporate Office
  • Via Visconti di Modrone, 18
  • 20122 Milan(Lombardy)
  • Italy
+39 02
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Vertical(s)
Life Sciences
Corporate Office
  • Via Visconti di Modrone, 18
  • 20122 Milan(Lombardy)
  • Italy
+39 02

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Enthera Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
4. Later Stage VC (Series A) 28-Jan-2021 $42.6M Completed Clinical Trials - Phase 1
3. Seed Round 24-Jul-2018 Completed Pre-Clinical Trials
2. Early Stage VC 10-May-2018 Completed Pre-Clinical Trials
1. Seed Round 01-Oct-2016 Completed Pre-Clinical Trials
To view Enthera’s complete valuation and funding history, request access »

VC Exit Predictor

See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.

Opportunity Score

Calculated using Exit Type probabilities, the company’s stage, and PitchBook’s historical returns data.

Exit Type

Evaluates the likelihood of a successful exit for investors, and the most likely exit type.

Request a free trial

Enthera Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Developer of biotherapeutics intended to treat auto-immune disorders. The company's pipelined products target pathways i
Drug Discovery
Milan, Italy
16 As of 2025

Cambridge, MA

La Jolla, CA
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Enthera Competitors (28)

One of Enthera’s 28 competitors is AnTolRx, a Formerly VC-backed company based in Cambridge, MA.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
AnTolRx Formerly VC-backed Cambridge, MA
Equillium Formerly VC-backed La Jolla, CA
Mitobridge Formerly VC-backed Cambridge, MA
Stealth BioTherapeutics Private Equity-Backed Needham, MA
Metabolic Solutions Development Company Venture Capital-Backed Kalamazoo, MI
You’re viewing 5 of 28 competitors. Get the full list »

Enthera Patents

  • 19

    Total Documents Applications and Grants

  • Total Patents Families

  • 4

    Granted

  • 11

    Pending

  • Expiring in next 12 mo

Enthera Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
EP-4537907-A1 Cd248 inhibitors and uses thereof Pending 10-Oct-2023
CA-3162043-A1 Antibody inhibitors of igfbp5 Pending 20-Feb-2020
AU-2021225061-A1 Inhibitors and uses thereof Inactive 20-Feb-2020
EP-3868396-A1 Inhibitors and uses thereof Inactive 20-Feb-2020
EP-4106804-A1 Inhibitors and uses thereof Pending 20-Feb-2020 C07K16/18
To view Enthera’s complete patent history, request access »

Enthera Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Enthera Investors (10)

Investor Name Investor Type Holding Investor Since Participating Rounds
AbbVie Ventures Corporate Venture Capital Minority
Banca Profilo Asset Manager Minority
Banor Sim Family Office Minority
Landmark Capital (Italy) Family Office Minority
Roche Venture Fund Corporate Venture Capital Minority
You’re viewing 5 of 10 investors. Get the full list »

Ready to get started?

Request a free trial

Enthera FAQs

  • When was Enthera founded?

    Enthera was founded in 2016.

  • Where is Enthera headquartered?

    Enthera is headquartered in Milan, Italy.

  • What is the size of Enthera?

    Enthera has 16 total employees.

  • What industry is Enthera in?

    Enthera’s primary industry is Drug Discovery.

  • Is Enthera a private or public company?

    Enthera is a Private company.

  • What is Enthera’s current revenue?

    The current revenue for Enthera is .

  • How much funding has Enthera raised over time?

    Enthera has raised $47.2M.

  • Who are Enthera’s investors?

    AbbVie Ventures, Banca Profilo, Banor Sim, Landmark Capital (Italy), and Roche Venture Fund are 5 of 10 investors who have invested in Enthera.

  • Who are Enthera’s competitors?

    AnTolRx, Equillium, Mitobridge, Stealth BioTherapeutics, and Metabolic Solutions Development Company are some of the 28 competitors of Enthera.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read blog »

  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process »